Evidence map›Paper›PMID 39941888›Full record

ArticleCancers2025

Real-World Efficacy and Toxicity of Ipilimumab and Nivolumab as First-Line Treatment of Metastatic Renal Cell Carcinoma (mRCC) in a Subpopulation of Elderly and Poor Performance Status Patients.

Noa Shani Shrem, Ana-Alicia Beltran-Bless, Sunita Ghosh, Camilla Tajzler, Lori A Wood, Christian Kollmannsberger, Naveen S Basappa, Jeffrey Graham, Nazanin Fallah-Rad, Daniel Y C Heng and 9 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancers, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

19 authors.

Noa Shani ShremThe Legacy Heritage Oncology Center & Dr. Larry Norton Institute, Soroka University Medical Center, Beer Sheva 84101, Israel.
Ana-Alicia Beltran-BlessDivision of Medical Oncology, University of Ottawa, Ottawa, ON K1H 8M5, Canada.ORCID 0000-0003-4880-8167
Sunita GhoshFaculty of Medicine and Dentistry, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Camilla TajzlerCentre of Innovative Medicine, Research Institute-McGill University Health Centre, Montreal, QC H3H 2R9, Canada.
Lori A WoodCapital Health Queen Elizabeth II Hospital, Halifax, NS B3H 2Y9, Canada.ORCID 0000-0003-2405-0216
Christian KollmannsbergerBC Cancer, Vancouver, BC V3V 1Z2, Canada.
Naveen S BasappaCross Cancer Institute, University of Alberta, Edmonton, AB T6G 2R3, Canada.
Jeffrey GrahamCancerCare Manitoba, Winnipeg, MB R3E 0V9, Canada.
Nazanin Fallah-RadUniversity Health Network, Toronto, ON M5G 2C4, Canada.
Daniel Y C HengAlberta Health Services, Calgary, AB T5J E34, Canada.
Denis SoulièresCentre Hospitalier de l'Université de Montréal, Montreal, QC H2X 0A9, Canada.ORCID 0000-0002-1533-3815
Aly-Khan A LalaniJuravinski Cancer Centre, McMaster University, Hamilton, ON L8V 5C2, Canada.ORCID 0000-0002-9907-9112
Rodney H BreauDivision of Urology, Department of Surgery, University of Ottawa, Ottawa, ON K1H 8M5, Canada.
Antonio FinelliUniversity Health Network, Toronto, ON M5G 2C4, Canada.
Simon TanguayMcGill University Health Centre, Montreal, QC H4A 3J1, Canada.ORCID 0000-0001-6947-304X
Bimal BhindiAlberta Health Services, Calgary, AB T5J E34, Canada.
Georg BjarnasonSunnybrook Health Sciences Centre, Toronto, ON M4N 3M5, Canada.
Frederic PouliotCentre Hospitalier Universitaire de Québec, Quebec, QC G1R 2J6, Canada.ORCID 0000-0002-6651-1079
Christina CanilDivision of Medical Oncology, University of Ottawa, Ottawa, ON K1H 8M5, Canada.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundIpilimumab and nivolumab (ipi/nivo) improved overall survival (OS) compared to sunitinib in the pivotal Checkmate 214 trial of metastatic renal cell carcinoma (mRCC) with International Metastatic RCC Database Consortium (IMDC) intermediate/poor risk disease. We evaluated the efficacy and toxicity of ipi/nivo in older and frailer populations in a real-world mRCC cohort.

methodsAnalysis was conducted on a real-world cohort with mRCC (N = 551) treated with first-line ipi/nivo from the Canadian Kidney Cancer information system (CKCis) database from January 2014 to December 2021. A comparison was made between outcomes and toxicity in patients 1. <70 versus (vs.) ≥70 yo, 2. <75 vs. ≥75 yo, and 3. KPS ≥70 vs. <70 yo. OS, progression-free survival (PFS), and time to treatment failure (TTF) were calculated by Kaplan-Meier analysis. Log-rank tests were used for comparison between groups.

resultsIpi/nivo treatment had no impact on survival outcomes or toxicity for patients >70 yo and >75 yo when controlled for IMDC. However, when comparing patients with KPS > 70 vs. KPS < 70, patients with a poor performance status had decreased median OS at 54.5 m vs. 10.8 m (

conclusionsThe use of ipi/nivo in mRCC demonstrated similar survival outcomes and toxicity in an older patient population. In patients with a poor performance status, it was associated with inferior OS and PFS. We believe that ipi/nivo is a reasonable treatment option for these patient populations, particularly in older patients.

Indexed as

efficacyelderlyipilimumab and nivolumablow KPSmetastatic renal cell carcinomapoor performance statusreal-world evidencetoxicity

Identifiers

PMID39941888
PMCPMC11816257

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.